Facile One-Pot Synthesis of Methyl 1-Aryl-1<i>H</i>
-1,2,4-triazole-3-carboxylates from Nitrilimines with Vilsmeier Reagent
作者:Shuo-En Tsai、Kun-Heng Chiang、Ching-Chun Tseng、Nai-Wei Chen、Ching-Yuh Chern、Fung Fuh Wong
DOI:10.1002/ejoc.201801808
日期:2019.2.28
A selective and convenient one‐pot methods have been developed for the synthesis of 1,2,4‐triazoles and methyl 1H‐1,2,4‐triazole‐3‐carboxylates by using hydrazonoyl hydrochlorides (nitrilimines) with Vilsmeier reagent. 2‐Amino‐2‐(2‐arylhydrazono)acetates were prepared from 2‐chloro‐2‐(2‐arylhydrazono)acetates with bis(trimethylsilyl)amine [NH(SiMe3)2] as the isolated intermediates for the further mechanistic
已经开发了一种选择性方便的单罐方法,该方法是通过使用肼基酰基盐酸盐(硝化亚胺)和Vilsmeier试剂来合成1,2,4-三唑和1 H - 1,2,4-三唑-3-羧酸甲酯。2-氨基-2-(2-芳基肼基)乙酸酯是由2-氯-2-(2-芳基肼基)乙酸酯与双(三甲基甲硅烷基)胺[NH(SiMe 3)2 ]作为分离的中间体制备的,用于进一步的机理研究。
CXCR7 antagonists
申请人:CHEMOCENTRYX, INC.
公开号:US10287292B2
公开(公告)日:2019-05-14
Compounds having formula I,
or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
具有式 I 的化合物、
本发明提供了具有式 I 的化合物或其药学上可接受的盐、水合物或 N-氧化物,可用于与 CXCR7 结合,治疗至少部分依赖于 CXCR7 活性的疾病。因此,本发明在进一步的方面提供了含有一种或多种上述化合物与药学上可接受的赋形剂混合的组合物。
US9169261B2
申请人:——
公开号:US9169261B2
公开(公告)日:2015-10-27
US9783544B2
申请人:——
公开号:US9783544B2
公开(公告)日:2017-10-10
[EN] CXCR7 ANTAGONISTS<br/>[FR] ANTAGONISTES DE CXCR7
申请人:CHEMOCENTRYX INC
公开号:WO2014085490A1
公开(公告)日:2014-06-05
Compounds having formula (I) (structurally represented) or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing the compounds in admixture with a pharmaceutically acceptable excipient.